Neurocrine Biosciences, Inc. (NBIX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
22.67
↓-47% vs avg
5yr avg: 42.92
30Y Low12.4·High74.4
P/FCF
↓
20.05
↓-35% vs avg
5yr avg: 30.80
30Y Low8.1·High88.9
P/B Ratio
↓
4.71
↓-18% vs avg
5yr avg: 5.78
30Y Low1.2·High26.9
ROE
↑
16.4%
↓+36% vs avg
5yr avg: 12.1%
30Y Low-251%·High95%
Debt/EBITDA
↓
0.64
↓-59% vs avg
5yr avg: 1.57
30Y Low0.4·High9.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NBIX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Neurocrine Biosciences, Inc. trades at 32.0x earnings, 46% below its 5-year average of 58.9x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 43%. On a free-cash-flow basis, the stock trades at 20.1x P/FCF, 35% below the 5-year average of 30.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $15.0B | $14.5B | $14.2B | $13.3B | $11.8B | $8.3B | $9.4B | $10.3B | $6.8B | $6.8B | $3.4B |
| Enterprise Value | $14.7B | $14.2B | $14.4B | $13.5B | $11.8B | $8.4B | $9.6B | $10.7B | $7.1B | $6.9B | $3.3B |
| P/E Ratio → | 32.03 | 30.37 | 41.49 | 53.34 | 76.56 | 92.58 | 23.04 | 275.62 | 324.59 | — | — |
| P/S Ratio | 5.25 | 5.08 | 6.01 | 7.05 | 7.93 | 7.36 | 8.96 | 13.06 | 15.10 | 42.29 | 223.72 |
| P/B Ratio | 4.71 | 4.47 | 5.47 | 5.96 | 6.92 | 6.07 | 8.32 | 16.16 | 14.17 | 18.37 | 10.66 |
| P/FCF | 20.05 | 19.42 | 25.40 | 36.80 | 36.58 | 35.77 | 43.08 | 77.78 | 88.94 | — | — |
| P/OCF | 19.18 | 18.57 | 23.77 | 34.13 | 34.80 | 32.51 | 41.02 | 70.00 | 67.18 | — | — |
P/E links to full P/E history page with 30-year chart
NBIX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Neurocrine Biosciences, Inc.'s enterprise value stands at 22.7x EBITDA, 47% below its 5-year average of 42.9x. The Healthcare sector median is 14.4x, placing the stock at a 58% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.98 | 6.10 | 7.15 | 7.93 | 7.44 | 9.18 | 13.54 | 15.65 | 43.00 | 218.17 |
| EV / EBITDA | 22.67 | 21.93 | 24.06 | 49.54 | 44.64 | 74.41 | 55.94 | 133.83 | 172.92 | — | — |
| EV / EBIT | 23.77 | 22.37 | 23.47 | 34.16 | 47.44 | 66.33 | 68.81 | 135.97 | 134.98 | — | — |
| EV / FCF | — | 19.02 | 25.80 | 37.29 | 36.58 | 36.20 | 44.11 | 80.68 | 92.16 | — | — |
NBIX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Neurocrine Biosciences, Inc. earns an operating margin of 21.6%. Operating margins have expanded from 13.3% to 21.6% over the past 3 years, signaling improving operational efficiency. ROE of 16.4% indicates solid capital efficiency. ROIC of 16.1% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.2% | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% |
| Operating Margin | 21.6% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% |
| Net Profit Margin | 16.7% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.4% | 16.4% | 14.2% | 12.7% | 10.0% | 7.2% | 46.2% | 6.6% | 5.0% | -41.5% | -38.2% |
| ROA | 11.5% | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% |
| ROIC | 16.1% | 16.1% | 16.4% | 9.1% | 11.7% | 5.4% | 10.3% | 6.2% | 4.5% | -27.4% | -38.0% |
| ROCE | 17.4% | 17.4% | 19.6% | 11.3% | 13.6% | 6.1% | 14.2% | 8.8% | 4.4% | -23.9% | -37.6% |
NBIX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Neurocrine Biosciences, Inc. carries a Debt/EBITDA ratio of 0.6x, which is very conservative (81% below the sector average of 3.3x). The company holds a net cash position — cash of $713M exceeds total debt of $415M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.18 | 0.19 | 0.15 | 0.32 | 0.37 | 0.78 | 0.81 | 0.99 | — |
| Debt / EBITDA | 0.64 | 0.64 | 0.76 | 1.57 | 0.99 | 3.88 | 2.40 | 6.21 | 9.52 | — | — |
| Net Debt / Equity | — | -0.09 | 0.09 | 0.08 | 0.00 | 0.07 | 0.20 | 0.60 | 0.51 | 0.31 | -0.26 |
| Net Debt / EBITDA | -0.46 | -0.46 | 0.37 | 0.65 | 0.00 | 0.88 | 1.31 | 4.80 | 6.05 | — | — |
| Debt / FCF | — | -0.40 | 0.40 | 0.49 | 0.00 | 0.43 | 1.03 | 2.90 | 3.22 | — | — |
| Interest Coverage | — | — | 4.84 | 85.83 | 35.07 | 4.93 | 4.25 | 2.45 | 1.71 | -6.30 | — |
Net cash position: cash ($713M) exceeds total debt ($415M)
NBIX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Neurocrine Biosciences, Inc.'s current ratio of 3.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.45x to 3.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 | 1.47 | 8.36 | 10.20 | 10.21 |
| Quick Ratio | 3.30 | 3.30 | 3.28 | 2.40 | 2.64 | 3.83 | 5.30 | 1.44 | 8.24 | 10.18 | 10.21 |
| Cash Ratio | 1.99 | 1.99 | 2.12 | 1.58 | 1.84 | 2.89 | 4.29 | 1.19 | 7.38 | 9.48 | 10.11 |
| Asset Turnover | — | 0.62 | 0.63 | 0.58 | 0.63 | 0.55 | 0.60 | 0.60 | 0.45 | 0.20 | 0.04 |
| Inventory Turnover | 0.76 | 0.76 | 0.59 | 1.04 | 0.66 | 0.47 | 0.36 | 0.43 | 0.45 | 1.22 | — |
| Days Sales Outstanding | — | 87.64 | 74.25 | 84.97 | 85.81 | 59.73 | 54.83 | 58.63 | 46.44 | 70.29 | — |
NBIX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Neurocrine Biosciences, Inc. returns 1.1% to shareholders annually primarily through share buybacks. The earnings yield of 3.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.4% | 0.3% | — | — |
| FCF Yield | 5.0% | 5.2% | 3.9% | 2.7% | 2.7% | 2.8% | 2.3% | 1.3% | 1.1% | — | — |
| Buyback Yield | 1.1% | 1.2% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.1% | 1.2% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $103M | $104M | $101M | $99M | $98M | $98M | $96M | $95M | $88M | $87M |
Peer Comparison
Compare NBIX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NBIXYou | $15B | 32.0 | 22.7 | 20.1 | 98.2% | 21.6% | 16.4% | 16.1% | 0.6 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 AXSM | $11B | -59.8 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INTR | $3B | 11.4 | 17.3 | 4.9 | 42.4% | 10.9% | 13.2% | 3.9% | 15.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full NBIX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See NBIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBIX vs INVA
Side-by-side business, growth, and profitability comparison vs Innoviva, Inc..
Start ComparisonNBIX — Frequently Asked Questions
Quick answers to the most common questions about buying NBIX stock.
What is Neurocrine Biosciences, Inc.'s P/E ratio?
Neurocrine Biosciences, Inc.'s current P/E ratio is 32.0x. The historical average is 48.6x. This places it at the 50th percentile of its historical range.
What is Neurocrine Biosciences, Inc.'s EV/EBITDA?
Neurocrine Biosciences, Inc.'s current EV/EBITDA is 22.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 43.8x.
What is Neurocrine Biosciences, Inc.'s ROE?
Neurocrine Biosciences, Inc.'s return on equity (ROE) is 16.4%. The historical average is -21.7%.
Is NBIX stock overvalued?
Based on historical data, Neurocrine Biosciences, Inc. is trading at a P/E of 32.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Neurocrine Biosciences, Inc.'s profit margins?
Neurocrine Biosciences, Inc. has 98.2% gross margin and 21.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Neurocrine Biosciences, Inc. have?
Neurocrine Biosciences, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.